CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 26, 2019-- Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced the closing of an underwritten public offering of 4,600,000 shares of its common stock, at a public offering price of $32.50 per share, including 600,000 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were $149.5 million.

Jefferies, BMO Capital Markets, Stifel and Guggenheim Securities acted as joint book-running managers for the offering. Baird acted as lead manager for the offering.

The securities described were offered by Ra Pharma pursuant to a shelf registration statement on Form S-3 (No. 333-231320), including a base prospectus. The securities were offered only by means of a prospectus. A final prospectus related to the offering was filed with the SEC and is available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com; BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, by telephone at 800-414-3627 or by email at bmoprospectus@bmo.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at 415-364-2720 or by email at syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ra Pharmaceuticals, Inc.

Ra Pharma is a clinical-stage biopharmaceutical company focused on leading the field of complement biology to bring innovative and accessible therapies to patients with rare diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190726005338/en/

Source: Ra Pharmaceuticals, Inc.

Investors:
Ra Pharmaceuticals, Inc.
Natalie Wildenradt, 617-674-9874

Media:
Argot Partners
David Rosen, 212-600-1902